The above literature supports the rationale for innovative tissue-targeted PPK therapeutic herpes vaccines, specifically designed to boost the number, longevity, and function of CD4+ and CD8+ TRM cells in ganglionic and mucosal sites, thereby strengthening protective immunity against virus reactivation from sensory neurons and reducing recurrent herpes infection and disease. This evidence concerns the gene CD4 and Herpesviridae infectious disease.